NewsBenzingaCORREZIONE: BorgWarner alza la guidance dell’EPS rettificato per l’esercizio 2026 da $5,05-$5,30 a $5,20-$5,35, rispetto a una stima di $5,21; restringe la guidance sui ricavi per l’esercizio 2026 da $14,000 miliardi-$14,300 miliardi a $14,000... CORREZIONE: BorgWarner alza la guidance dell’EPS rettificato per l’esercizio 2026 da $5,05-$5,30 a $5,20-$5,35, rispetto a una stima di $5,21; restringe la guidance sui ricavi per l’esercizio 2026 da $14,000 miliardi-$14,300 miliardi a $14,000... Benzinga 2026.10.29 13:13 (GMT+0) Open on Benzinga Other news ConocoPhillips Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Reported Earlier, Comstock Resources Q3 Adj. EPS $0.02 Misses $0.04 Estimate, Sales $384.363M Miss $424.364M Estimate Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Reported Earlier, Gold Royalty Q3 Adj. EPS $0.02 Beats $0.01 Estimate, Sales $10.246M Beat $8.235M Estimate Bithumb to Delist Fetch.ai (FET) on December 7 Sony Group Q2 EPS ¥76.48, Sales ¥3.429T
ConocoPhillips Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Reported Earlier, Comstock Resources Q3 Adj. EPS $0.02 Misses $0.04 Estimate, Sales $384.363M Miss $424.364M Estimate
Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval
Reported Earlier, Gold Royalty Q3 Adj. EPS $0.02 Beats $0.01 Estimate, Sales $10.246M Beat $8.235M Estimate
